×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Kidney Cancer
Brielle Urciuoli
The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.
Kristie L. Kahl
After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.
Daniel George, MD, discusses the physical and emotional burden of kidney cancer and explains the importance of finding resources to help with patient and family support.
Daniel George, MD, educates viewers on newer therapies that show promise in treating more aggressive forms of kidney cancer.
Daniel George, MD, provides an overview of available treatment options in kidney cancer and remarks on the value of patient–physician collaboration in managing the disease.
Daniel George, MD, discusses the different ways in which kidney cancer may present and highlights the most common symptoms that lead to a diagnosis.
The Food and Drug Administration (FDA) has approved a supplemental biologics license application adding a four-week dosing schedule for Opdivo (nivolumab) across several of the PD-1 inhibitor’s indications.
Jason M. Broderick
A new combination – Keytruda (pembrolizumab) plus Lenvima (lenvatinib) – was granted a breakthrough therapy designation to treat patients with advanced and/or metastatic renal cell carcinoma (RCC).
Cabometyx (cabozantinib) was granted approval by the Food and Drug Administration (FDA) for previously untreated patients who have advanced renal cell carcinoma (RCC).
Jason M. Broderick
Frontline Opdivo (nivolumab) plus Yervoy (ipilimumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat patients with intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).